59 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
17 Jan 24
Report of Foreign Private Issuer
8:02am
the osteoarthritis vertical to include moderate and severe osteoarthritis patients, who comprise the majority segment of the knee osteoarthritis population” said
6-K
ENLV
Enlivex Therapeutics Ltd
2 Nov 23
Report of Foreign Private Issuer
4:30pm
required majority, each of the proposals that were described in the Company’s Notice and Proxy Statement for the Meeting that was attached as Exhibit
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
) will constitute a quorum.
The approval of each of the proposals requires the affirmative vote of a majority of the ordinary shares present, in person … subject to the fulfillment of one of the following additional voting requirements: (i) a majority of the shares held by shareholders who
424B5
ENLV
Enlivex Therapeutics Ltd
30 Dec 22
Prospectus supplement for primary offering
4:01pm
1% of the voting rights, or by shareholders holding at least 5% of the voting rights of the company.
Majority vote. Except as otherwise provided … by the holders of a majority of our voting rights represented at the meeting in person or by proxy and voting thereon. In the case of an equality of votes
6-K
EX-99.1
cx1xtvilhaovx2zk9le
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
6-K
EX-99.1
nn4 vuxinbue3xj
29 Apr 22
Report of Foreign Private Issuer
8:15am
F-3
m2f1ln068 lp
29 Apr 22
Shelf registration (foreign)
8:14am
6-K
EX-99.2
8602hxf89esyfydpgquz
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
6-K
EX-99.1
n1unjl36sdm
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
6-K
EX-10.1
5ueubgqx pp8p921iyk
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
424B5
lo1j0unwy 87g
10 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
x1tsz55 1lg7g74
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-99.1
gcycm5r
3 Feb 21
Current Report
7:55am
6-K
EX-99.1
qvhtf l5v6rfkkc5i28
21 Dec 20
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
8:02am
6-K
EX-99.1
yxjyt
3 Nov 20
Current report (foreign)
9:14am
424B5
t59kos4kd e3t3
22 Oct 20
Prospectus supplement for primary offering
8:45am
6-K
EX-99.1
cv1mwspoilb7s1wfg
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am